Valley is aware of the nationwide supply disruption of IV fluid solution due to Hurricane Helene, and wants to reassure the community that steps have been taken to ensure the situation will have no negative impact on our patients and the community.
Hypertrophic cardiomyopathy (HCM) is a genetically transmitted disease – seen in about 1 out of 500 people – that results in localized areas of heart muscle thickening (hypertrophied). There are two main types of HCM: non-obstructive – seen in about two-thirds of patients – and obstructive – seen in about one-third of patients. In the obstructive HCM type, the thickening of the heart muscle impedes the heart’s ability to pump the blood into the body. It can affect people of all ages and has a normal life expectancy when managed appropriately.
Many people are unaware they have hypertrophic cardiomyopathy as there are often no symptoms. When symptoms are traced to this condition, they typically include abnormal heart rhythm (arrhythmia), shortness of breath, fainting (syncope), swelling in the legs, or chest pain.
Some patients with HCM are at higher risk for dangerous arrhythmias, which can lead to sudden cardiac death. A more in-depth evaluation of this risk is necessary.
Hypertrophic cardiomyopathy can be diagnosed in a variety of ways including:
Valley has state-of-the-art resources to assure guideline-directed assessment and treatment tailored for your hypertrophic cardiomyopathy. Your treatment plan may include one or more options based on your overall health and your specific needs, including: